Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carbidopa/levodopa products may induce vitamin B6 deficiency and seizures.

The American journal of nursing·2026
Same author

True generic of Flovent HFA inhaler now approved.

The American journal of nursing·2026
Same author

Second drug approved for achondroplasia.

The American journal of nursing·2026
Same author

Updates from the FDA on GLP-1 agonists.

The American journal of nursing·2026
Same author

More warnings about over-the-counter supplements containing hidden drugs.

The American journal of nursing·2026
Same author

Drug for iron deficiency is now approved for pediatric patients.

The American journal of nursing·2026

Related Experiment Video

Updated: Sep 22, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K

FDA Evaluating Possible Serious Risks From Umbralisib.

Diane S Aschenbrenner1

  • 1Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .

The American Journal of Nursing
|May 26, 2022
PubMed
Summary

Umbralisib (Ukoniq) may increase risks when combined with a monoclonal antibody for chronic lymphocytic leukemia. Close monitoring for adverse effects is crucial for patients undergoing lymphoma treatment.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.9K

Related Experiment Videos

Last Updated: Sep 22, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.9K

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Umbralisib (Ukoniq) is approved for marginal zone lymphoma and follicular lymphoma.
  • Chronic lymphocytic leukemia (CLL) is a type of B-cell leukemia.

Purpose of the Study:

  • To evaluate the safety of umbralisib when used with a specific monoclonal antibody in treating chronic lymphocytic leukemia.
  • To identify potential risks and adverse events associated with this combination therapy.

Main Methods:

  • Analysis of initial clinical trial data.
  • Observational study of patient outcomes and adverse events.

Main Results:

  • Umbralisib, when administered with a specific monoclonal antibody for CLL, may elevate the risk of mortality and severe adverse events.
  • Patients undergoing lymphoma treatment with umbralisib require vigilant monitoring for side effects.

Conclusions:

  • Healthcare providers must closely monitor patients for adverse effects when using umbralisib.
  • Reporting of adverse events to the Food and Drug Administration's MedWatch program is essential for patient safety.